Viatris will sell the biosimilars business of the former Mylan to the Indian drugmaker Biocon for as much as $3.3 billion.
Dreamstime
Text size
Viatris
,
the company formed in 2020 through a merger of the generic drugmaker Mylan with a
Pfizer
division, said Monday that it would sell Mylan’s old…
